Sanofi India Limited, along with Sanofi Healthcare India Private Limited, has joined hands with Cipla Limited to announce an exclusive distribution partnership aimed at expanding the reach of Sanofi India's Central Nervous System (CNS) product range across India.

Under this collaboration, Cipla will undertake the distribution and promotion of Sanofi India's six CNS brands, including the renowned Frisium®, a leading name in the anti-epileptic medication category. While Sanofi India will retain ownership and continue to manage the manufacturing and importing processes of its complete CNS product line, Cipla will leverage its extensive network and robust marketing infrastructure to enhance accessibility to these treatments across the country.

Rodolfo Hrosz, Managing Director of Sanofi India Limited, expressed confidence in the partnership, stating, "Sanofi India's CNS products are esteemed leaders in their respective categories, significantly impacting the lives of patients in urban areas. Partnering with Cipla will enable us to extend the reach of this portfolio to healthcare professionals and patients nationwide."

Achin Gupta, CEO of One India Business at Cipla Limited, emphasized the company's commitment to improving access to high-quality treatments, particularly in challenging therapeutic areas like CNS. He remarked, "Enhancing access to highly efficacious and quality therapeutic solutions in CNS aligns with our purpose of 'Caring for Life'. This collaboration with Sanofi India represents a significant step forward in addressing the unmet needs of patients in this critical medical domain."

Sanofi India remains steadfast in its dedication to accelerating innovation and expanding its robust pipeline across various therapeutic areas, including Diabetes, Transplants, Rare Diseases, Consumer Healthcare, and Vaccines. This strategic partnership with Cipla marks a significant milestone in its mission to enhance patient care and improve healthcare accessibility across India.